| Date | Time | Source | Headline | Symbol | Company |
| 07/03/2024 | 1:00PM | iHub Newswire | FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent | | |
| 09/12/2022 | 8:05AM | TipRanks | JonesTrading Remains a Sell on Deciphera Pharmaceuticals (DCPH) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 09/12/2022 | 7:31AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 09/12/2022 | 12:25AM | TipRanks | JMP Securities Reaffirms Their Buy Rating on Deciphera Pharmaceuticals (DCPH) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 09/11/2022 | 6:30AM | Business Wire | Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 09/10/2022 | 9:00AM | Business Wire | Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 09/01/2022 | 7:00AM | Business Wire | Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/25/2022 | 5:32PM | TipRanks | DCPH Stock Has Outperformed, Should Investors Buy? | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/19/2022 | 4:05PM | Business Wire | Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/11/2022 | 8:27AM | TipRanks | J.P. Morgan Sticks to Their Hold Rating for Deciphera Pharmaceuticals (DCPH) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/11/2022 | 6:05AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/10/2022 | 4:20PM | Business Wire | Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/08/2022 | 4:15PM | TipRanks | JonesTrading Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/08/2022 | 2:45AM | TipRanks | Barclays Sticks to Its Sell Rating for Deciphera Pharmaceuticals (DCPH) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/05/2022 | 1:06AM | TipRanks | Deciphera Pharmaceuticals (DCPH) Gets a Buy Rating from JMP Securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/04/2022 | 4:10PM | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/04/2022 | 7:11AM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/04/2022 | 7:08AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 08/04/2022 | 7:00AM | Business Wire | Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 07/28/2022 | 7:00AM | Business Wire | Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022 | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 07/15/2022 | 4:20PM | Business Wire | Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/24/2022 | 4:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/21/2022 | 4:38PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |